Abstract Library

#4232 Aurora kinase A inhibition as a promising therapeutic strategy in ARID1A-mutated neuroendocrine carcinomas: First results of an in vitro and in vivo study

Introduction: Neuroendocrine carcinomas of the gastrointestinal tract (GEP-NEC) are rare but extremely aggressive tumor diseases with a 5-year survival rate of approximately 25%. The inactivating ARID1A mutation can be detected in approximately 40% of cases of GEP-NEC. Previous studies have shown that Aurora kinase A inhibition leads to selective synthetic lethality of ARID1A-deficient colorectal tumor cells.

Conference:

Presenting Author:

Authors: Viol F, Amin T, Sipos B, Fründt T, Smolkova B,

Keywords: Neuroendocrine Carcinoma, Mutation based Therapy, ARID1A, Aurora Kinase A,

#2974 MEK/RAF and PARP as Novel Targets in Neuroendocrine Neoplasms – First Results from a Molecular in vitro Tumor Board

Introduction: Neuroendocrine neoplasms (NEN) are a heterogeneous group comprising well differentiated neuroendocrine tumors (NET) and poorly differentiated neuroendocrine carcinomas (NEC). Although, major progress has been made in the development of targeted therapies in various cancers, establishment of a promising personalized therapy in NEN is still pending. So far, a lack of suitable preclinical models represent a major challenge concerning the validation of a mutational based targeted therapy (MBTT)

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Viol F, Sipos B, Amin T, Fahl M, Grabowski P,

Keywords: Neuroendocrine neoplasms, Personalized therapy, Preclinical in vitro models, Mutational based targeted therapy,

#2239 pNET G3 Tumor Stabilization Achieved by an Individualized Molecular Therapy Based on Tumor Genome Sequencing Results

Introduction: High-grade pancreatic neuroendocrine neoplasms (pNENs) constitute a heterogeneous group of malignant neoplasms, encompassing neuroendocrine tumors (NET) G3 and carcinomas (NEC). Due to poor data on NET G3 tumors no standard therapy in metastatic disease could be established so far. Tumor genome sequencing might help to better profile NET G3 tumors and could provide novel opportunities for individualized and thereby successful patient specific treatments.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Steurer M

Authors: Steurer M, Lauer U, Hinterleitner C, Sipos B, la Fougère C,

Keywords: NET G3, tumor genome sequencing, individual therapy,

#1490 Even Malignant Appendiceal Neuroendocrine Tumors Exhibit No Recurrent Chromosomal Alterations

Introduction: Neuroendocrine tumors (NETs) of the midgut are located in the ileum (iNET), caecum or appendix (aNET). Despite of the similar origin, NETs of the ileum and the appendix behave remarkably different. iNETs show high malignant potential, which manifests with early lymph node or liver metastases. Genetically, the loss of chromosome 18 (Ch18) in 60-74% of cases is the most frequent alteration in iNETs. aNETs are often incidental findings, rarely show metastases, and no chromosomal alterations are known.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Sipos B

Authors: Nann D, Nieser M, Sperveslage J, Henopp T, Vokuhl C,

Keywords: NET,

#1484 Neuroendocrine Tumors of the Appendix Are Probably Harmless Neoplasms

Introduction: Appendiceal neuroendocrine tumors (aNETs) have a 5-year survival rate between 74% and 95% according to recent data from Cancer Registry of Norway and the United States, respectively. However, in the daily clinical practice one almost never encounters patients suffering from aNETs with distant metastasis or dying of the disease.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Sipos B

Authors: Weysser A, Nieser M, Kloeppel G, Sipos B,

Keywords: NET,